PHAXIAM Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

PHAXIAM Therapeutics ha un patrimonio netto totale di €25.6M e un debito totale di €10.2M, che porta il suo rapporto debito/patrimonio netto a 39.8%. Le sue attività totali e le sue passività totali sono rispettivamente €51.3M e €25.7M.

Informazioni chiave

39.8%

Rapporto debito/patrimonio netto

€10.20m

Debito

Indice di copertura degli interessi	n/a
Contanti	€10.47m
Patrimonio netto	€25.61m
Totale passività	€25.70m
Totale attività	€51.31m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €16.2M ) di PHXMP superano le sue passività a breve termine ( €15.3M ).

Passività a lungo termine: Le attività a breve termine di PHXMP ( €16.2M ) superano le sue passività a lungo termine ( €10.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: PHXMP ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di PHXMP è aumentato da 1.4% a 39.8% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: PHXMP ha una liquidità sufficiente per 5 mesi in base all'ultimo reportfree cash flow, ma da allora ha raccolto ulteriori capitali.

Previsione Cash Runway: Dati insufficienti per determinare se PHXMP ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

PHAXIAM Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

ERYTECH Announces Receipt of Nasdaq Notice

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

No longer forecast to breakeven

No longer forecast to breakeven

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane